ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In this study, we investigated the cytotoxic activity and possible mechanisms of action of a hybrid compound of BA and brosimine B in CML BCR-ABL + cell lines that are sensitive (K-562) and resistant (K-562R) to imatinib.